Jan 13,2022

Karkinos Healthcare raises funds from Endiya Partners

The start-up is currently backed by Tata Group, Reliance Digital Health and Rakuten Medical, along with a number of eminent industrialists such as Ratan Tata and Venu Srinivasan

FUNDING SEED ROUND
View Analyst & Ambassador Comments
Go to original news
Jan 24,2022

CUREETY, the French start-up specialized in data and remote-monitoring in oncology, raises €5 million

CUREETY, the leading remote-monitoring start-up in the field of digital oncology, announced that it has raised five million euros in funding. This financing round was led by French health insurance companies with the support of Cureety's existing investors, bank pool and the public investment bank bpifrance. The transaction coincides in France with the new Social Security financing law allowing for the reimbursement of remote-monitoring solutions starting in 2022.

FUNDING SERIES A
View Analyst & Ambassador Comments
Go to original news
Jan 25,2022

Reimagine Care Secures $25 Million in Series A Funding to Drive Commercialization of Home-Centered, Value-Based Cancer Care

Reimagine Care, an innovative provider of technology-enabled services that supports oncologists in delivering high-quality, home-centered, value-based cancer care, today announced it has completed a $25 million capital raise led by Sante Ventures, Martin Ventures, and LRVHealth. The funding will be leveraged to further develop and commercialize the company's first-of-its kind technology-enabled services platform, launch the virtual care center, and expand the patient care team. Several strategic investors joined the financing round including the CU Healthcare Innovation Fund, a strategic healthcare fund affiliated with the University of Colorado Anschutz Medical Campus; City of Hope, a National Cancer Institute-designated comprehensive cancer center and founding member of the National Comprehensive Cancer Network; McKesson Ventures; and Sable Investments.

FUNDING SERIES A
View Analyst & Ambassador Comments
Go to original news
Feb 04,2022

£5m for AI cancer detection platform C the Signs

C the Signs has raised £5 million of investment to move closer to its mission to create a future where every patient survives cancer. It hopes the investment from MMC, Ataraxia and Acequia Capital, alongside notable angels including the past CEO of AXA Health, past CEO of Bupa and founder of Monzo, will be transformative in driving forward plans to scale the impact of the technology to accelerate early cancer detection and survival. The firm was founded by two NHS doctors, Dr Bea Bakshi and Dr Miles Payling, following the loss of a patient due to a delayed cancer diagnosis.

FUNDING SERIES A
View Analyst & Ambassador Comments
Go to original news
Feb 07,2022

Med tech startup bags £3.2 million for early cancer diagnosis from the U.K. government

Health tech company working on early detection of lung cancer, Qure.ai has won £3.2 million from the U.K. governement's Small Business Research Initiative Healthcare. The Small Business Research Initiative grant is provided in partnership with the NHS Cancer Programme and the Accelerated Access Collaborative. The SBRI competition was launched in March 2021. Qure.ai was among the eight startups that received funding for their projects that assist in faster and earlier detection and diagnosis of cancer. The fresh capital will be used to conduct a research programme analysing the detection of lung nodules on chest X-rays that are indicative of lung cancer to gather evidence and better understand the feasibility of AI triage of questionable chest X-rays for prompt reporting.

FUNDING GRANT
View Analyst & Ambassador Comments
Go to original news
Feb 15,2022

Bristol Myers Squibb Prices $6 Billion of Senior Unsecured Notes

Bristol-Myers Squibb Company (NYSE:BMY) today announced that it has priced a public offering (the �Offering�) of senior unsecured notes in a combined aggregate principal amount of $6 billion (collectively, the �Notes�). The Notes will be issued in four tranches: (i) $1,750,000,000 in aggregate principal amount of 2.950% notes due 2032, (ii) $1,250,000,000 in aggregate principal amount of 3.550% notes due 2042, (iii) $2,000,000,000 in aggregate principal amount of 3.700% notes due 2052, and (iv) $1,000,000,000 in aggregate principal amount of 3.900% notes due 2062. Bristol Myers Squibb expects that the closing of the Offering will occur on March 2, 2022, subject to the satisfaction of customary closing conditions.

FUNDING POST-IPO DEBT
View Analyst & Ambassador Comments
Go to original news
Mar 03,2022

CancerIQ Raises $14M Series B Funding to Improve Access to Innovations in Cancer Early Detection and Prevention

CancerIQ, the platform powering early cancer detection and prevention across broad patient populations, announced today it closed a $14 million Series B financing round co-led by Merck Global Health Innovation Fund (Merck GHI) and Amgen Ventures. McKesson Ventures, OSF Ventures (the investment arm of OSF HealthCare, a current CancerIQ customer), as well as CancerIQ�s Series A lead investor, HealthX Ventures, also participated in the Series B round. The new funding will help CancerIQ grow its precision health platform, strengthen its partnership ecosystem, and expand its health system network. Following a recent series of key executive hires, the company also plans to hire 50 team members to meet the rising demand for more efficient and innovative cancer prevention services.

FUNDING SERIES B
View Analyst & Ambassador Comments
Go to original news
Mar 17,2022

Canopy raises $13 million to improve oncology practices

Canopy, which develops an Intelligent Care Platform (ICP) for oncology, announced on Thursday that it has raised $13 million in funding led by GSR Ventures, with participation from Samsung Next, UpWest, and other industry leaders and executives, such as Geoff Calkins (former SVP Product, Flatiron Health), and Chris Mansi (CEO Of Viz.AI). Formerly known as Expain, Canopy will use the funding to make its platform generally available to cancer treatment centers across the U.S., and recruit 40 additional employees for its R&D center in Israel, which currently employs 30 people

FUNDING SERIES A
View Analyst & Ambassador Comments
Go to original news
Mar 23,2022

AstraZeneca takes $33 million stake in UK health tech startup Huma that helps doctors conduct clinical trials virtually

Today, British pharmaceuticals giant AstraZeneca announced it has invested $33 million (about �25 million) in the company as part of a broader commercial tie-up between the two firms, according to a report from CNBC citing a person familiar with the matter. The deal marks a rare start-up investment for AstraZeneca.

FUNDING FUNDING ROUND
View Analyst & Ambassador Comments
Go to original news
Mar 29,2022

ConcertAI Raises $150M In Series C at $1.9 Billion Valuation

ConcertAI, a Cambridge, MA-based provider of enterprise AI and real-world data (RWD) solutions for life sciences and healthcare, raised $150M in Series C funding at a $1.9 billion valuation. The round was led by Sixth Street. Sixth Street Managing Director Adam Kaye will be joining ConcertAI�s board of directors, with Managing Director Lee Mooney joining as a board observer. The company intends to use the funds to expand operations and its business reach.

FUNDING SERIES C
View Analyst & Ambassador Comments
Go to original news
Subscribe to FUNDING